Progressive systemic sclerosis (PSS) is a multisystem disorder characterized by a combination of widespread vascular disease, fibrosis and atrophy. In the skin the most conspicuous changes are those caused by the excess synthesis of new collagen leading to tethering of the skin and multiple contractures. Raynaud's phenomenon and ischemic lesions of the fingers are common and are due to vascular obstruction.
The mechanical properties of collagen depend upon intermolecular crosslinks. When the collagen is newly formed these crosslinks are readily reducible and can be detected by borohydride reduction. D-penicillamine is able to cleave newly formed crosslinks from dermal collagen (Herbert et al. 1974 ), but there have been conflicting reports of its potential value for clinical disease. We here report data on 22 patients with PSS treated with D-penicillamine, comparing the relative progress of the cutaneous, functional, peripheral vascular and visceral manifestations of the disease.
Subjects, Treatment and Assessments Twenty-two patients with systemic sclerosis (18 females, 4 males), of ages between 20 and 65 years were assessed before and regularly throughout therapy with D-penicillamine. The assessments included:
Cutaneous Involvement
(1) An objective description of dermal involvement was recorded with particular reference to the extent and severity of thickening and tethering of the skin.
(2) The patients were asked for their subjective opinion of the progress of the skin involvement since their previous visit and to state whether the skin was improved, the same or worse. They were specifically asked not to include under this heading Raynaud's phenomenon, ulcers or contractures.
Based on these two findings, conclusions were drawn as to whether the skin disease had improved, remained unchanged or advanced.
Peripheral Vascular Disease
(1) Raynaud's phenomenon. The patients were questioned as to their cold sensitivity and whether this had improved, remained the same or deteriorated.
(2) The incidence and extent of ulceration of the finger tips was noted.
Based on these two findings an estimate of whether the peripheral vascular disease had improved, remained unchanged or deteriorated was obtained.
Joint Function
(1) Grip strength: this was determined by asking the patient to squeeze a grip-strength bag inflated at 50 mmHg and recording the maximum sustained pressure in each hand. For the purposes of the overall analysis the two were summed together and sequential measurements compared.
(2) Finger-palm flexion: this was documented by asking the patient to make a fist and recording the minimum distances between the nail tips of the index and middle fingers and the transverse palmar crease. The results for both fingers of both hands were summed together.
(3) Elbow extension: fixed flexion contractures of each elbow were measured with a goniometer. (4) Jaw opening: the inter-incisor distance was measured with a calibrated plastic triangle placed between the teeth.
Based on these four measurements the progress ofjoint function was documented and conclusions were drawn for each patient as to whether they had improved, remained unchanged or advanced.
Visceral Involvement
All patients initially received a full physical examination and various investigations, including barium swallow, barium meal and lung function tests whenever appropriate, and the incidence and extent of visceral complications of the disease were noted. Routine investigations at follow-up included examination of urine and measurement of the blood urea. We repeated pulmonary function studies, and in particular diffusing capacity (Ogilvie et al. 1957) in selected patients with known pulmonary involvement before penicillamine therapy.
Particular attention was paid to determine development, advancement or regression of visceral disease.
Administration ofD-penicillamine D-penicillamine was given either as the base or the hydrochloride, 125 mg of the former being equivalent to 150 mg of the latter. For the purposes of this paper all doses are reported as their equivalent as penicillamine base. The starting dose was 125 or 250 mg per day, and was increased cautiously at about four-week intervals by similar amounts until eithei there was evidence of clinical improvement or the dose was limited by side-effects. During the incremental period the blood was monitored weekly for hemoglobin, white cell and platelet counts, and the urine for protein and blood. Subsequently these checks were performed monthly.
RESULTS

Dose ofD-pencillamine
Twenty-two patients were treated with Dpenicillamine. In 7 patients there were sideeffects attributable to the drug, and these are shown in Table 1 . In 2, side-effects led to discontinuation of therapy, and a further 5 had limited dose tolerance, the maximum being 375 mg per day. In the remaining 15 patients ( Table 2 ) the dose varied between 250 and 1250 mg per day. The duration of therapy varied between four months and four years.
Cutaneous Involvement
Well-documented objective descriptions and subjective impressions of improvement of the cutaneous manifestations occurred in 15 patients. No such improvement occurred in 7 patients. Five remained unchanged, 3 having severe disease with gross skin changes. Two deteriorated despite D-penicillamine, 750 and 1000 mg/day, and one of these died from acute renal failure.
Of the 15 who showed initial improvement, 2 relapsed while on continued therapy. In one of these further increase in dosage was limited by gastrointestinal side-effects, and in the other a severe relapse was accompanied by acute renal failure from which she died. Two patients developed side-effects leading to withdrawal or reduction in dosage of the drug, and both subsequently developed an exacerbation of the skin changes. In one this was accompanied by acute renal involvement which led to death.
Of the 11 patients showing definite cutaneous improvement, the skin thickening and tethering cleared completely in 4, and was considerably better in the remaining 7. Because of complete remission of skin involvement, the drug was withdrawn from 2 patients. Relapses with return of skin thickening and tethering occurred in both, but they remitted on restarting D-penicillamine. However, among these 11 patients, one developed visceral involvement (gastrointestinal), 3 showed persistant visceral involvement that failed to improve (all pulmonary), and 2 died from advancing visceral involvement (cardiac and gastrointestinal, and cardiac and pulmonary).
Therefore, there were 5 patients with cutaneous improvement who were free from development, persistence or progression of visceral disease.
Joint Function
Adequate data were available in 18 of the 20 patients tolerating the drug to determine alterations in movements of joints. In 7 there was overall significant improvement, in 7 there was no change, and in 4 there was marked deterioration. All the 7 who improved showed marked cutaneous responses. However, 2 developed side-effects from D-penicillamine, limiting the dose used. Four patients had visceral manifestations of the disease, and apart from possible improvement of dysphagia in one, no benefit occurred. This was particularly illustrated by repeated pulmonary function tests (Fig 1) in 3 with pulmonary fibrosis. One of these patients developed acute renal failure and died, but she was on low-dose therapy because of side-effects. There were 3 patients with improvements in joint function and no visceral problems. (Table 3) In no patient was there definite improvement in Raynaud's phenomenon. Although 3 showed healing of finger ulcers, it was uncertain whether this was due to D-penicillamine or more likely to better care and protection of the hands. We conclude that penicillamine has no influence on peripheral vascular disease.
Peripheral Vascular Disease
Visceral Complications
Before starting D-penicillamine therapy, 8 of these 22 patients had symptoms of dysphagia from involvement of the cesophagus, and 8 showed involvement of the lungs. On treatment with Dpenicillamine (Table 4 ) one claimed symptomatic improvement of dysphagia, 5 remained unchanged, and 2 showed advancing gastrointestinal involvement developing the typical malabsorption syndrome associated with PSS.
There were 2 patients who had no cesophageal symptoms before starting D-penicillamine, but in whom barium swallow examinations revealed disordered cesophageal motility. One of these developed dysphagia at the same time as rapid progression of cutaneous involvement, flexion contractures and renal failure. There was one patient with no cesophageal symptoms before Eight patients showed pulmonary involvement and particularly impairment of diffusing capacity. One with minor impairment of gas transfer showed possible improvement. In 6 with marked impairment, there was no significant change and one died from respiratory failure and terminal bronchopneumonia. Of these 8, 4 showed definite cutaneous improvement and 2 improvement in joint function (Fig 1) despite the failure of pulmonary function to improve. Two patients developed fatal cardiomyopathies thought to be visceral manifestations of PSS while on the drug. In neither was post-mortem material available to confirm this diagnosis. One further patient died from isch;emic heart disease. I Three patients with previously documented normal renal function developed acute renal failure over a few weeks. Despite peritoneal I dialysis in 2, they died. Postmortem examinations of the kidneys revealed the typical changes of 0 PSS with intimal proliferation in the interlobular arteries, areas of fibrinoid necrosis in small blood vessels and multiple small infarcts. There were none of the changes of penicillamine nephrotoxicity. One of these three had shown a good cutaneous response to D-penicillamine, but had developed severe skin reactions to the drug and *-NW-==.* after initially receiving 500 mg/day could subsequently only tolerate 125 mg of D-penicillamine per day under steroid cover. A second patient had shown an initial good cutaneous response to 250 mg of D-penicillamine per day, but this proved transient and was followed by an acute cutaneous relapse accompanied by renal failure and malignant hypertension. A third patient with rapidly advancing cutaneous and joint function changes showed no response and developed acute renal failure despite 750 mg of D-penicillamine per day.
In summary, of 22 patients treated with Dpenicillamine for systemic sclerosis, 8 showed advancement of visceral manifestations, 6 dying directly from these complications (Table 5 ). There was one further death from unrelated causes. In other patients visceral involvement remained unchanged except for 2 showing possible improvement. Although 15 patients showed cutaneous improvement, only 5 could be regarded as having an overall good result because of side-effects, relapses, and development, persistence or advancement of visceral involvement in the others. With regard to functional improvement, 7 showed some benefit, but only 3 had such benefit without persisting or advancing visceral disease. There was no improvement in peripheral vascular manifestations.
Discussion
In PSS there is a wide variety of cutaneous and visceral features. These changes are due to a combination of widespread vascular disease, excess collagen synthesis and fibrosis, and ischemic atrophy. Vascular damage in the limbs will lead to Raynaud's phenomenon and atrophy and ulceration of the pulps of the finger pads. The thickening and tethering of the skin is due to the widespread proliferation of collagen in the dermis. Often there is a poor correlation between peripheral vascular disease and the extent of skin involvement (Dabich et al. 1972 ). Peripheral vascular disease may antedate the skin disease and vice versa, and patients may be observed with severe ischemic ulceration of the fingers but little or no thickening and tethering of the skin. Likewise they may have severe skin changes but no evidence of vascular obstruction. The joint contractures characteristic of systemic sclerosis are only partly due to collagen proliferation in the skin. There are also gross adhesions within tendon sheaths limiting tendon function, and in the joint capsule with scar formation. The functional tests used in this study all reflect involvement of the tendons and joints as well as the cutaneous changes. It is therefore important to consider such tests separately from those reflecting dermal involvement and peripheral vascular disease.
The fundamental pathological change of systemic sclerosis probably occurs in the small arteries and arterioles with concentric intimal proliferation which may obstruct their lumen. Sometimes there is fibrosis of the adventitia. This change is seen in the kidneys, lungs, and other organs (D'Angelo et al. 1969 , Trell & Lindstrom 1971 , Cannon et al. 1974 , Campbell & Le Roy 1975 . There is a considerable reduction in the numbers of capillaries, and those that remain become dilated and telangiectatic (Norton et al. 1968 , Maricq & Le Roy 1973 .
The resultant ischemia could not only produce atrophy of the tissues but also stimulate collagen synthesis ) and so lead to the cutaneous changes. The nature of the collagen in blood vessel basement membrane and that proliferating in intimal fibrosis is not as yet determined, but it could well be resistant to the lathyritic action of D-penicillamine. This would explain why the drug does not seem to influence the peripheral vascular and visceral manifestations of PSS. Excess synthesis of collagen in the skins of patients with PSS has been demonstrated by electron microscopy, revealing fine immature collagen fibrils with incomplete cross-banding and beaded filaments typical of newly formed collagen (Hayes & Rodnan 1971 , Fleischmajer et al. 1972 ), increased solubility of dermal collagen (Uitto et al. 1971) , elevated levels of the enzyme protocollagen proline hydroxylase (Uitto et al. 1969 , Keiser et al. 1971 ), excess reducible crosslinks (Herbert et al. 1974 ) and measurements of the rates of collagen synthesis by PSS fibroblasts in vitro (Le Roy 1972 and .
The strength of collagen depends upon the integrity of crosslinks between the molecules. The chemical structure of these crosslinks has been described by Bailey et al. (1974) . There are two types of reducible crosslinks, one of which, the aldimine, can be cleaved by D-penicillamine forming stable thiazolidine complexes, but the other keto crosslink is resistant to this agent. In skin the crosslink is predominantly of the aldimine form, whereas in other tissues both may be present in varying proportions. Moreover, as collagen matures the crosslinks become stabilized in some unknown fashion and resistant to chemical attack (Robins et al. 1973) . In PSS the involved tissues show a mixture of ischmmic atrophy and accumulation of collagen of varying degrees of maturity. Therefore, it is likely that any response to D-penicillamine will be variable and most obvious in the purely cutaneous manifestations of the disease.
Despite the undoubted and well-documented changes in dermal collagen induced by Dpenicillamine (Nimni et al. 1972 , Harvey et al. 1974 , Francis & Mowat 1974 , Herbert et al. 1974 , the value of the drug for PSS has not been established. Thus Bluestone et al. (1970) failed to find any clinical benefit in 9 patients receiving the drug, yet by a suction cup technique noted improvement in pliability of the skin in 6 subjects. Moynahan (1973) found that intractable morphcea resolved with this drug. Fulghun (1968) did not notice any improvement on D-penicillamine therapy. There are no studies examining the influence of D-penicillamine on visceral manifestations of PSS.
We interpret the clinical and experimental data as showing that D-penicillamine is effective on the purely dermal aspects of disease, and acts by cleaving newly formed labile aldimine crosslinks. It probably will not affect the collagen proliferating in the lumen of small blood vessels, in tendon sheaths and in synovium and joint capsule. As all the more readily reproducible tests of limb involvement depend upon observation and measurement of ischmmic changes, and upon recording the range and power of joint movements, the purely cutaneous benefits are extremely difficult to monitor. Moreover, it seems likely that only active early cutaneous disease has the potential to respond to this drug.
It seems unlikely that D-penicillamine could have been responsible for advancement of visceral manifestations in some patients and particularly in those that died. The 3 patients with acute renal failure had the most rapidly progressing cutaneous disease with short histories before therapy, and histological examination of the kidneys revealed the typical features of PSS (Cannon et al. 1974) . One of the patients with cardiac failure and the patient with respiratory failure had gross generalized disease before treatment, and both continued to deteriorate slowly.
Side-effects from D-penicillamine were common in this group of patients, and either caused withdrawal or limited the dose used in 7 of 22 patients. This incidence is similar to that observed when using the drug for rheumatoid arthritis. For example, the Multicentre Trial Group (1973) withdrew 16 of 41 rheumatoid patients for these reasons. Six patients died from the disease, having received therapy in periods varying between a few months and several years. A further patient died from ischmmic heart disease. Therefore, the mortality over periods varying up to four years was 34%, in contrast with the 27% five-year mortality found by Bennett et al. (1971) . As this is an uncontrolled survey and many patients in the present series were specifically referred because of advancing disease, it is difficult to make valid comparisons, but it seems likely that D-penicillamine makes no difference to the visceral progress of PSS.
Therapeutic agents with some more fundamental action are required in order to control the vascular and visceral features of the disease. Analogues of proline become incorporated within newly synthesized collagen polypeptide chains. As they do not act as substrates for proline hydroxylase the formation of collagen is limited (Uitto & Prockop 1975 , Chvapil 1975 . However, the effectiveness of these agents in vivo is in doubt , Chvapil et al. 1974 ) and potential alteration of the structure of body proteins carries unknown biological risks. Colchicine experimentally interacts with microtubules (Borisy & Taylor 1967) and inhibits the secretion of procollagen from fibroblasts and the synthesis of collagen (Ehrlich et al. 1974) . Alarcon-Segovia et al. (1974) have presented preliminary data suggesting that colchicine will benefit cutaneous manifestations of PSS, but there is no information regarding visceral complications.
Summary
Twenty-two patients with progressive systemic sclerosis were treated with D-penicillamine in doses ranging up to 1250 mg/day for periods varying between a few months and four years. Side-effects occurred in 7 patients, necessitating drug withdrawal in 2. Cutaneous benefit occurred in 15 patients, but owing to side-effects from the drug, relapses, and development, persistence or advancement of visceral complications, an overall good result only occurred in 5. Seven patients showed improvements in joint function, but only 3 were regarded as having an overall good result. Peripheral vascular disease and visceral involvement seemed not to be influenced by D-penicillamine and sometimes appeared or advanced during treatment. Six patients died from visceral manifestations of systemic sclerosis and one from another cause. D-penicillamine is of limited value for the cutaneous features of progressive systemic sclerosis, but probably of no value for the vascular and visceral manifestations of the disease. Uitto 
DISCUSSION
Dr R Grahame (London): Although your successes were modest, 1 feel that they are singularly more impressive than the results of a study in which I collaborated about eight years ago with Dr R Bluestone and Dr P J L Holt at the Hammersmith Hospital. I have been wondering why Dr Jayson's results are so much better than ours with regard to the skin, and there seem to be two possible reasons. First, I suspect that the patients who were admitted to the earlier trial had much more advanced and established systemic sclerosis. Secondly, and more important, the dose schedule used in our study was much in excess of that used by Dr Jaysonit was about twice his dose. Therefore there was a much higher drop-out rate and, consequently, patients did not receive treatment for long periods. I wonder whether the advice to anyone planning to treat scleroderma patients with penicillamine should be 'go low, go slow' and start early. Dr Jayson: Our message was that, as far as we could ascertain, penicillamine has something useful to offer in the purely cutaneous manifestations, but only in early disease and not in the grossly advanced cases.
Dr D N Golding (Harlow): Dr Jayson pointed out that his measurements of function of the hand depend on skin thickening, tethering of the tendons and the joint capsules. Should not inflammatory changes in the joints be considered too? Do some of these patients have coincident rheumatoid disease? Even if not, is it not a fact that patients with systemic sclerosis may have inflammatory changes in the small joints, in which case perhaps it is this inflammation which is being reduced by the drug and this accounts for the observed improvement? Dr Jayson: They certainly have a concomitant synovitis. We are now carrying out a survey, and it appears that this can be much more common than has been appreciated. It can be missed in view of the gross thickening of the skin, and involvement of the small joints can be difficult to appreciate. From technetium scanning, which we are now doing, there seems to be inflammation in many of these joints.
Dr S Jain (London): As I understand it, Dr Jayson's study did not have a control group. Could not some of the improvements in the measured parameters be the result of patients learning the movements being measured ? Dr Jayson: It is certainly a gross defect not to have a control group. We are conscious of this defect, but it js difficult in a long-drawn-out disease of considerable variability to have an adequate control group. The iniprovements in joint function, when they were present, were very dramatic and were always correlated with considerable improvement in cutaneous manifestations. We felt that they were real improvements, but I agree that we could do with a control.
Dr I H Scheinberg (Chairman): Did not 2 of the patients act as their own controls in that they relapsed after withdraWat of the drug, but cleared a second time after it was reinstituted? In a clinical study that is not a bad kind of conitrol to have.
Dr Jayson: Yes, that is right.
Dr G Holti (Newcastle upon Tyne): May I9first express sympathy with Dr Jayson because I have over 60 patients with progressive systeniic sclerosis. To mount a cont4$lled trial on these is very difficult because the severity of the disease varies in all of them. [t is difficult to divide them equally.
May I plead for more measurements on these patients'? As dermatologists, we have spread unholy confusion by introducing such terms as localized scleroderma and generalized morphcea, in which the entire skin may be affected yet without any Raynaud's phenomenon or any visceral involvement, so that they do extremely well on penicillamine.
I am rather sceptical about the role of penicillamine in systemic sclerosis. But, with modern gadgets, it is possible to carry out noninvasive measurements of the elastic properties of skin collagen. After only a few days on steroids or penicillamine, it is possible to assess whether or not the elastic properties of the collagen have been altered in these patients. Skin thickness can be measured, being due to collagen, only by X-ray methods which are highly specialized.
There is usually much cedema in systemic sclerosis skin. As in dermatomyositis and SLE, the tendency to cedema and to increased capillary permeability is high.
A number of techniques are available to measure stretchability. W'e use home-made instruments. They are fairly complex but can be made by any university department of mechanical engineering. If anyone is interested I will gladly give them details later.
Dr Scheinberg: Dr Nimni, have you any experience with progressive systemic sclerosis, or any comments to add to the discussion ? Dr Nimni: No, I have no such experience. From what is known about the turnover of collagen and from what we can expect to occur during tissue remodelling or breakdown, such as happens during periods of rapid growth, collagen seems to turn over at a relatively fast rate. At this stage there are significant amounts of the aldimine crosslinks which have not become further stabilized. At this stage it is reasonable to expect that penicillamine will either interrupt the formation of crosslinks, or break down the small number of incompletely stabilized crosslinks.
In the mature state, unless the disease itself, as a result of its-inflammatory nature, accelerates localized turnover, it is difficult to envisage how the drug could be effective. This is especially true of the advanced stages, in which there is a massive amount of fibrotic tissue and where collagenolytic activity is almost absent.
Thus, it makes sense to think in terms of its efficacy in situations in which there is rapid turnover of collagen, and of its ineffectiveness when collagen turnover is absent. It would be interesting to pursue the suggestion of looking at collagenase in these tissues. There have been some observations suggesting that collagenolytic activity is decreased in scleroderma. Perhaps it would be worth trykig to discover whether penicillamine affects the collagenolytic pathway.
